Tesaglitazar
Encyclopedia
Tesaglitazar is a peroxisome proliferator-activated receptor
agonist with affinity to PPARα and PPARγ, proposed for type 2 diabetes.
The drug had completed several phase III clinical trials, however in May, 2006 AstraZeneca
announced that it had discontinued further development.
Peroxisome proliferator-activated receptor
In the field of molecular biology, the peroxisome proliferator-activated receptors are a group of nuclear receptor proteins that function as transcription factors regulating the expression of genes...
agonist with affinity to PPARα and PPARγ, proposed for type 2 diabetes.
The drug had completed several phase III clinical trials, however in May, 2006 AstraZeneca
AstraZeneca
AstraZeneca plc is a global pharmaceutical and biologics company headquartered in London, United Kingdom. It is the world's seventh-largest pharmaceutical company measured by revenues and has operations in over 100 countries...
announced that it had discontinued further development.